DK4221709T3 - Imidazopiperazin-hæmmere af transkriptionsaktiverende proteiner - Google Patents

Imidazopiperazin-hæmmere af transkriptionsaktiverende proteiner

Info

Publication number
DK4221709T3
DK4221709T3 DK21876484.3T DK21876484T DK4221709T3 DK 4221709 T3 DK4221709 T3 DK 4221709T3 DK 21876484 T DK21876484 T DK 21876484T DK 4221709 T3 DK4221709 T3 DK 4221709T3
Authority
DK
Denmark
Prior art keywords
imidazopiperazine
transcription
inhibitors
activating proteins
proteins
Prior art date
Application number
DK21876484.3T
Other languages
English (en)
Inventor
Kang Le
Michael Soth
Philip Jones
Jason Cross
Timothy Mcafoos
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of DK4221709T3 publication Critical patent/DK4221709T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK21876484.3T 2020-10-02 2021-09-30 Imidazopiperazin-hæmmere af transkriptionsaktiverende proteiner DK4221709T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063086728P 2020-10-02 2020-10-02
PCT/US2021/052898 WO2022072648A1 (en) 2020-10-02 2021-09-30 Imidazopiperazine inhibitors of transcription activating proteins

Publications (1)

Publication Number Publication Date
DK4221709T3 true DK4221709T3 (da) 2026-04-07

Family

ID=80950902

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21876484.3T DK4221709T3 (da) 2020-10-02 2021-09-30 Imidazopiperazin-hæmmere af transkriptionsaktiverende proteiner

Country Status (11)

Country Link
US (1) US12559497B2 (da)
EP (1) EP4221709B1 (da)
JP (1) JP2023544173A (da)
KR (1) KR20230080441A (da)
CN (1) CN116261454A (da)
AU (1) AU2021355480B2 (da)
CA (1) CA3193745A1 (da)
DK (1) DK4221709T3 (da)
IL (1) IL301707A (da)
MX (1) MX2023003785A (da)
WO (1) WO2022072648A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4221708A4 (en) 2020-10-02 2024-11-06 Board of Regents, The University of Texas System IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS
CA3193745A1 (en) 2020-10-02 2022-04-07 Kang Le Imidazopiperazine inhibitors of transcription activating proteins
AU2024331409A1 (en) * 2023-08-30 2026-03-12 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as cbp/p300 degraders and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1537114T3 (da) 2002-08-07 2006-11-13 Novartis Ag Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
MX2008015008A (es) 2006-05-26 2008-12-05 Novartis Ag INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA.
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
WO2008078291A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
CN101686989B (zh) * 2007-06-21 2016-10-19 卡拉治疗学股份有限公司 取代的咪唑并杂环
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
CN101468988A (zh) 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
CN102076694A (zh) 2008-06-25 2011-05-25 埃科特莱茵药品有限公司 5,6,7,8-四氢-咪唑并[1,5-a]吡嗪化合物
WO2011092120A1 (en) 2010-01-29 2011-08-04 Nerviano Medical Sciences S.R.L. 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
US9145418B2 (en) 2011-10-07 2015-09-29 Nerviano Medical Sciences S.R.L. Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
CN103087067A (zh) 2012-08-02 2013-05-08 盛世泰科生物医药技术(苏州)有限公司 作为二肽基酶抑制剂的化合物及其组合物,以及它们的用途
US9695176B2 (en) 2012-10-18 2017-07-04 Bristol-Myers Squibb Company Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists
US9371282B2 (en) * 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
MX382033B (es) * 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
JP6820254B2 (ja) 2014-10-10 2021-01-27 ジェネンテック, インコーポレイテッド 治療用化合物およびその使用
EP3632915A1 (en) * 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
EP3445750A4 (en) 2016-04-18 2019-11-27 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
JP7014736B2 (ja) 2016-05-24 2022-02-01 ジェネンテック, インコーポレイテッド がんの処置のためのピラゾロピリジン誘導体
EP3464270B1 (en) 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
RU2020131507A (ru) 2018-03-29 2022-05-04 Боард Оф Реджентс, Де Юниверсити Оф Техас Систем Имидазопиперазиновые ингибиторы белков-активаторов транскрипции
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
EP4221708A4 (en) 2020-10-02 2024-11-06 Board of Regents, The University of Texas System IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS
CA3193745A1 (en) 2020-10-02 2022-04-07 Kang Le Imidazopiperazine inhibitors of transcription activating proteins

Also Published As

Publication number Publication date
JP2023544173A (ja) 2023-10-20
AU2021355480A1 (en) 2023-05-04
EP4221709B1 (en) 2026-01-21
WO2022072648A1 (en) 2022-04-07
AU2021355480B2 (en) 2026-03-05
CA3193745A1 (en) 2022-04-07
CN116261454A (zh) 2023-06-13
US20230312588A1 (en) 2023-10-05
IL301707A (en) 2023-05-01
EP4221709A4 (en) 2024-10-02
KR20230080441A (ko) 2023-06-07
EP4221709A1 (en) 2023-08-09
MX2023003785A (es) 2023-04-26
US12559497B2 (en) 2026-02-24
AU2021355480A9 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
EP4069212A4 (en) HIF-2 ALPHA INHIBITORS
IL287787A (en) Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
IL287795A (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP4216951A4 (en) KRAS G12D INHIBITORS
EP4452974A4 (en) RAS ONCOPROTEIN INHIBITORS
DK4146348T3 (da) Inhibitorer af nek7-kinase
DK4221709T3 (da) Imidazopiperazin-hæmmere af transkriptionsaktiverende proteiner
IL288996A (en) Aminopyrimidine amide autophagy inhibitors and methods of use thereof
EP3801500A4 (en) Inhibitors of sarm1
IL277778B (en) Bcl6 inhibitors
EP4333821A4 (en) SARS-COV-2 INHIBITORS
DK3976597T3 (da) Småmolekylære inhibitorer af NF-KB-inducerende kinaser
EP4337203A4 (en) INHIBITORS OF THE MENIN-MLL INTERACTION
EP4244818A4 (en) Disambiguation of poses
HUE056885T2 (hu) CREB-kötõ fehérjék inhibitorai
EP4225310A4 (en) HETEROARYL AMIDE INHIBITORS OF CD38
EP4247372A4 (en) PLASMA KALLICREIN INHIBITORS
HUE065395T2 (hu) Mikromûanyagok elválasztása
EP4452967A4 (en) SARS-CoV-2 INHIBITORS
EP4305043A4 (en) Purification of sialooligosaccharides
EP4226919A4 (en) FERROPTOSIS INHIBITOR
EP4210694A4 (en) PLASMA KALLICREIN INHIBITORS
EP4384164A4 (en) HYPOXIA-INDUCIBLE FACTOR INHIBITORS
DK4192813T3 (da) Inhibitorer af transglutaminaser
EP4514131A4 (en) MODIFIED RELEASE OF ASCAROSIDES